{"id":11444,"date":"2025-06-02T06:41:00","date_gmt":"2025-06-02T10:41:00","guid":{"rendered":"https:\/\/sharewatch.com\/wp\/2025\/06\/02\/liquidia-corporation-announces-commercial-launch-of-yutrepia-for-treatment-of-pulmonary-arterial-hypertension-following-fda-approval-and-legal-ruling\/"},"modified":"2025-06-02T06:41:00","modified_gmt":"2025-06-02T10:41:00","slug":"liquidia-corporation-announces-commercial-launch-of-yutrepia-for-treatment-of-pulmonary-arterial-hypertension-following-fda-approval-and-legal-ruling","status":"publish","type":"post","link":"https:\/\/sharewatch.com\/wp\/2025\/06\/02\/liquidia-corporation-announces-commercial-launch-of-yutrepia-for-treatment-of-pulmonary-arterial-hypertension-following-fda-approval-and-legal-ruling\/","title":{"rendered":"Liquidia Corporation Announces Commercial Launch of YUTREPIA for Treatment of Pulmonary Arterial Hypertension Following FDA Approval and Legal Ruling"},"content":{"rendered":"<div class=\"layout__region nsdq-l-grid__item syndicated-article-body\">\n<section class=\"jupiter22-c-article-body\">\n<div class=\"body\">\n<div class=\"body__content\">\n<p>Liquidia announces FDA approval and commercial launch of YUTREPIA for treating pulmonary arterial hypertension and PH-ILD.<\/p>\n<h2>Quiver AI Summary<\/h2>\n<p>Liquidia Corporation has announced that its inhalation powder YUTREPIA\u2122 (treprostinil) is now available for prescription at specialty pharmacies, following FDA approval on May 23, 2025, for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). This significant step comes shortly after a court ruled against United Therapeutics&#8217; attempt to block YUTREPIA&#8217;s commercial launch due to a patent infringement claim. Liquidia&#8217;s CEO, Dr. Roger Jeffs, emphasized the company\u2019s rapid progress in making this innovative treatment available to patients, highlighting the urgency to provide a new therapeutic option. YUTREPIA distinguishes itself as a unique prostacyclin analog formulated for efficient lung delivery, addressing an important need in the treatment landscape of these serious conditions affecting over 100,000 patients in the U.S.<\/p>\n<div class=\"ads__inline\">\n<div id=\"js-dfp-tag-fnU\"  class=\"btf-bodymidpagetwothirdswidth-1\">          <script type=\"text\/javascript\">         googletag.cmd.push(function() {             \/\/ Check if ID matches ID in the window.adsList array before calling googletag.display             function isAdInAdsList(id) {             for (var i = 0; i < window.adsList.length; i++) {                 if (window.adsList[i].id === id) {                     return true;                 }             }             return false;         }         if (isAdInAdsList('js-dfp-tag-fnU')) {             googletag.display('js-dfp-tag-fnU');         }         });     <\/script> <\/div>\n<\/p><\/div>\n<h2>Potential Positives<\/h2>\n<ul>\n<li>YUTREPIA has received FDA approval, allowing for its commercial launch and prescription to patients via specialty pharmacies.<\/li>\n<li>The company achieved a rapid turnaround, making its first commercial shipment just five business days post-approval, indicating strong operational readiness.<\/li>\n<li>The U.S. District Court's denial of United Therapeutics\u2019 request for an injunction clears the way for Liquidia to proceed with the commercial launch without legal hindrances.<\/li>\n<li>Liquidia's CEO emphasized the strategic urgency in bringing YUTREPIA to market, positioning it as a leading therapy for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).<\/li>\n<\/ul>\n<h2>Potential Negatives<\/h2>\n<ul>\n<li>Potential legal risks remain as ongoing litigation with United Therapeutics could still affect the commercialization and future sales of YUTREPIA.<\/li>\n<li>The press release emphasizes the need for ongoing evaluation of YUTREPIA's integration into the market, indicating uncertainty regarding its acceptance and market penetration.<\/li>\n<li>The summary of safety information mentions significant potential side effects, including bleeding risks and hypotension, which may limit patient acceptance and raise concerns among prescribers.<\/li>\n<\/ul>\n<h2>FAQ<\/h2>\n<h3>When was YUTREPIA approved by the FDA?<\/h3>\n<p>YUTREPIA was approved by the FDA on May 23, 2025.<\/p>\n<h3>What conditions does YUTREPIA treat?<\/h3>\n<p>YUTREPIA is indicated for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).<\/p>\n<h3>How quickly was YUTREPIA launched after FDA approval?<\/h3>\n<p>YUTREPIA was launched just five business days after FDA approval.<\/p>\n<h3>What legal challenges did YUTREPIA face before launch?<\/h3>\n<p>A court denied United Therapeutics\u2019 request to block the commercialization of YUTREPIA.<\/p>\n<h3>What is unique about YUTREPIA's delivery method?<\/h3>\n<p>YUTREPIA is delivered as an inhaled dry-powder formulation through a compact, low-effort device.<\/p>\n<div class=\"ads__inline\">\n<div id=\"js-dfp-tag-Anc\"  class=\"btf-bodymidpagetwothirdswidth-2\">          <script type=\"text\/javascript\">         googletag.cmd.push(function() {             \/\/ Check if ID matches ID in the window.adsList array before calling googletag.display             function isAdInAdsList(id) {             for (var i = 0; i < window.adsList.length; i++) {                 if (window.adsList[i].id === id) {                     return true;                 }             }             return false;         }         if (isAdInAdsList('js-dfp-tag-Anc')) {             googletag.display('js-dfp-tag-Anc');         }         });     <\/script> <\/div>\n<\/p><\/div>\n<p>Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.<\/p>\n<p><\/p>\n<h2>$LQDA Insider Trading Activity<\/h2>\n<p>$LQDA insiders have traded $LQDA stock on the open market 20 times in the past 6 months. Of those trades, 0 have been purchases and 20 have been sales.<\/p>\n<p>Here\u2019s a breakdown of recent trading of $LQDA stock by insiders over the last 6 months:<\/p>\n<ul>\n<li>ROGER JEFFS  (Chief Executive Officer) has made 0 purchases and 2 sales selling 36,473 shares for an estimated <strong>$454,944<\/strong>.<\/li>\n<li>MICHAEL KASETA  (CFO and COO) has made 0 purchases and 3 sales selling 32,744 shares for an estimated <strong>$400,256<\/strong>.<\/li>\n<li>RUSSELL SCHUNDLER  (General Counsel) has made 0 purchases and 3 sales selling 23,420 shares for an estimated <strong>$286,276<\/strong>.<\/li>\n<li>RAJEEV SAGGAR  (Chief Medical Officer) has made 0 purchases and 4 sales selling 14,858 shares for an estimated <strong>$189,288<\/strong>.<\/li>\n<li>SCOTT MOOMAW  (Chief Commercial Officer) has made 0 purchases and 3 sales selling 12,314 shares for an estimated <strong>$151,008<\/strong>.<\/li>\n<li>JASON ADAIR  (Chief Business Officer) has made 0 purchases and 5 sales selling 8,020 shares for an estimated <strong>$99,871<\/strong>.<\/li>\n<\/ul>\n<p>To track insider transactions, check out Quiver Quantitative's insider trading dashboard.<\/p>\n<h2>$LQDA Hedge Fund Activity<\/h2>\n<p>We have seen 88 institutional investors add shares of $LQDA stock to their portfolio, and 89 decrease their positions in their most recent quarter.<\/p>\n<div class=\"ads__inline\">\n<div id=\"js-dfp-tag-m2g\"  class=\"btf-bodymidpagetwothirdswidth-3\">          <script type=\"text\/javascript\">         googletag.cmd.push(function() {             \/\/ Check if ID matches ID in the window.adsList array before calling googletag.display             function isAdInAdsList(id) {             for (var i = 0; i < window.adsList.length; i++) {                 if (window.adsList[i].id === id) {                     return true;                 }             }             return false;         }         if (isAdInAdsList('js-dfp-tag-m2g')) {             googletag.display('js-dfp-tag-m2g');         }         });     <\/script> <\/div>\n<\/p><\/div>\n<p>Here are some of the largest recent moves:<\/p>\n<ul>\n<li>LM ADVISORS LLC removed 2,206,443 shares (-100.0%) from their portfolio in Q1 2025, for an estimated <strong>$32,545,034<\/strong><\/li>\n<li>KYNAM CAPITAL MANAGEMENT, LP removed 1,632,526 shares (-72.0%) from their portfolio in Q1 2025, for an estimated <strong>$24,079,758<\/strong><\/li>\n<li>DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) added 1,616,778 shares (+inf%) to their portfolio in Q1 2025, for an estimated <strong>$23,847,475<\/strong><\/li>\n<li>JANUS HENDERSON GROUP PLC added 1,103,799 shares (+206.1%) to their portfolio in Q1 2025, for an estimated <strong>$16,281,035<\/strong><\/li>\n<li>WHITEFORT CAPITAL MANAGEMENT, LP removed 937,065 shares (-47.2%) from their portfolio in Q1 2025, for an estimated <strong>$13,821,708<\/strong><\/li>\n<li>FMR LLC added 899,606 shares (+4360.0%) to their portfolio in Q1 2025, for an estimated <strong>$13,269,188<\/strong><\/li>\n<li>FARALLON CAPITAL MANAGEMENT LLC added 700,000 shares (+21.3%) to their portfolio in Q1 2025, for an estimated <strong>$10,325,000<\/strong><\/li>\n<\/ul>\n<p>To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.<\/p>\n<h2>$LQDA Analyst Ratings<\/h2>\n<p>Wall Street analysts have issued reports on $LQDA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.<\/p>\n<p>Here are some recent analyst ratings:<\/p>\n<ul>\n<li>BTIG issued a \"Buy\" rating on 05\/27\/2025<\/li>\n<li>Scotiabank issued a \"Outperform\" rating on 05\/05\/2025<\/li>\n<\/ul>\n<p>To track analyst ratings and price targets for $LQDA, check out Quiver Quantitative's $LQDA forecast page.<\/p>\n<h2>$LQDA Price Targets<\/h2>\n<p>Multiple analysts have issued price targets for $LQDA recently. We have seen 3 analysts offer price targets for $LQDA in the last 6 months, with a median target of $19.0.<\/p>\n<p>Here are some recent targets:<\/p>\n<ul>\n<li>Andreas Argyrides from Oppenheimer set a target price of <strong>$13.0<\/strong> on 05\/19\/2025<\/li>\n<li>Greg Harrison from Scotiabank set a target price of <strong>$36.0<\/strong> on 05\/05\/2025<\/li>\n<li>Serge Belanger from Needham set a target price of <strong>$19.0<\/strong> on 01\/09\/2025<\/li>\n<\/ul>\n<h2>Full Release<\/h2>\n<p> <\/p>\n<ul>  <\/p>\n<li style=\"text-align:left;\">   YUTREPIA now available to be prescribed to patients via specialty pharmacies  <\/li>\n<p>  <\/p>\n<li style=\"text-align:left;\">   FDA approved YUTREPIA on May 23, 2025  <\/li>\n<p>  <\/p>\n<li style=\"text-align:left;\">   Court denies United Therapeutics\u2019 request for preliminary injunction and a temporary restraining order, clearing the path for full commercial launch\n<p>  <\/li>\n<p> <\/ul>\n<p> <\/p>\n<p>  MORRISVILLE, N.C., June  02, 2025  (GLOBE NEWSWIRE) -- Liquidia Corporation\u00a0(NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that Liquidia is scheduled to make its first commercial shipment of YUTREPIA\u2122 (treprostinil) inhalation powder, marking the first time YUTREPIA will be available to be prescribed to patients at specialty pharmacies. This milestone was achieved only five business days following the U.S. Food and Drug Administration (FDA) approval of YUTREPIA on May 23, 2025, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). <\/p>\n<div class=\"ads__inline\">\n<div id=\"js-dfp-tag-PAE\"  class=\"btf-bodymidpagetwothirdswidth-4\">          <script type=\"text\/javascript\">         googletag.cmd.push(function() {             \/\/ Check if ID matches ID in the window.adsList array before calling googletag.display             function isAdInAdsList(id) {             for (var i = 0; i < window.adsList.length; i++) {                 if (window.adsList[i].id === id) {                     return true;                 }             }             return false;         }         if (isAdInAdsList('js-dfp-tag-PAE')) {             googletag.display('js-dfp-tag-PAE');         }         });     <\/script> <\/div>\n<\/p><\/div>\n<p> <\/p>\n<p>  Dr.\u00a0Roger Jeffs, CEO,\u00a0Liquidia\u00a0said: \u201cWe have moved with exceptional speed to provide a new and differentiated therapeutic alternative to the marketplace. In just over one week, our sales force hit the ground running with the promotion of YUTREPIA, the product was listed with compendia, and commercial product was shipped to specialty pharmacies. This extraordinary pace is a direct result of our rigorous preparation and the strategic urgency driving our desire to provide patients immediate access to the unique attributes of YUTREPIA as we look to position it as the prostacyclin of first choice for patients with PAH and PH-ILD.\u201d <\/p>\n<p> <\/p>\n<p>  On May 30, 2025, the U.S. District Court for the Middle District of North Carolina denied United Therapeutics\u2019 (UTHR) request for a preliminary injunction and a temporary restraining order in its complaint filed against Liquidia (Case No. 1:25-cv-00368) alleging infringement of U.S. Patent No. 11,357,782 (the \u2018782 patent). UTHR sought to enjoin Liquidia from commercializing YUTREPIA for the treatment of patients with PAH and PH-ILD. The Court denied the request, in part, based on its conclusion that UTHR is not likely to succeed on the merits of its claims. Liquidia has also filed a motion to dismiss, stay or transfer UTHR\u2019s claims regarding the \u2018782 patent. That motion remains pending with the Court. With this denial, UTHR no longer has any motions pending that seek emergency relief to enjoin the launch of YUTREPIA. <\/p>\n<p> <\/p>\n<p>  <strong><br \/>   About Pulmonary Arterial Hypertension (PAH)<br \/>  <\/strong><\/p>\n<p>  Pulmonary arterial hypertension (PAH) is a rare, chronic, progressive disease caused by narrowing, thickening or stiffening of the pulmonary arteries that can lead to right heart failure and eventually death. Currently, an estimated 45,000 patients are diagnosed and treated in\u00a0the United States. There is currently no cure for PAH, so the goals of existing treatments are to alleviate symptoms, maintain or improve functional class, delay disease progression, and improve quality of life. <\/p>\n<p> <\/p>\n<p>  <strong><br \/>   About Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)<br \/>  <\/strong><\/p>\n<p>  Pulmonary hypertension (PH) associated with interstitial lung disease (ILD) includes a diverse collection of up to 200 different pulmonary diseases, including interstitial pulmonary fibrosis, chronic hypersensitivity pneumonitis, connective tissue disease-related ILD, and chronic pulmonary fibrosis with emphysema (CPFE) among others. Any level of PH in ILD patients is associated with poor 3-year survival. A current estimate of PH-ILD prevalence in\u00a0the United States\u00a0is greater than 60,000 patients, though population size in many of these underlying ILD diseases is not yet known due to factors including underdiagnosis and lack of approved treatments until\u00a0March 2021, when inhaled treprostinil was first approved for this indication. <\/p>\n<p> <\/p>\n<p>  <strong><br \/>   About YUTREPIA\u2122 (treprostinil) Inhalation Powder<br \/>  <\/strong><\/p>\n<p>  YUTREPIA is an inhaled dry-powder formulation of treprostinil delivered through a convenient, low-effort, palm-sized device. YUTREPIA was designed using Liquidia\u2019s PRINT<br \/>  <sup><br \/>   \u00ae<br \/>  <\/sup><br \/>  technology, which enables the development of drug particles that are precise and uniform in size, shape and composition, and that are engineered for enhanced deposition in the lung following oral inhalation.\u00a0Liquidia\u00a0has completed the INSPIRE trial (<\/p>\n<p>   NCT03399604<\/p>\n<p>  ), or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil, an open-label, multi-center phase 3 clinical study of YUTREPIA in patients diagnosed with PAH who are na\u00efve to inhaled treprostinil or who are transitioning from Tyvaso<br \/>  <sup><br \/>   \u00ae<br \/>  <\/sup><br \/>  (nebulized treprostinil). YUTREPIA is currently being studied in the ASCENT trial (<\/p>\n<p>   NCT06129240<\/p>\n<p>  ), or An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH, with the objective of informing YUTREPIA\u2019s dosing and tolerability profile in patients with PH-ILD. YUTREPIA was previously referred to as LIQ861 in investigational studies.<\/p>\n<p>  <strong><br \/>   INDICATION<br \/>  <\/strong><\/p>\n<p>  YUTREPIA (treprostinil) inhalation powder is a prostacyclin analog indicated for the treatment of: <\/p>\n<div class=\"ads__inline\">\n<div id=\"js-dfp-tag-bAQ\"  class=\"btf-bodymidpagetwothirdswidth-5\">          <script type=\"text\/javascript\">         googletag.cmd.push(function() {             \/\/ Check if ID matches ID in the window.adsList array before calling googletag.display             function isAdInAdsList(id) {             for (var i = 0; i < window.adsList.length; i++) {                 if (window.adsList[i].id === id) {                     return true;                 }             }             return false;         }         if (isAdInAdsList('js-dfp-tag-bAQ')) {             googletag.display('js-dfp-tag-bAQ');         }         });     <\/script> <\/div>\n<\/p><\/div>\n<p> <\/p>\n<ul type=\"disc\">  <\/p>\n<li style=\"margin-bottom:8pt;\">   Pulmonary arterial hypertension (PAH;\u00a0WHO Group\u00a01) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%).  <\/li>\n<p>  <\/p>\n<li style=\"margin-bottom:8pt;\">   Pulmonary hypertension associated with interstitial lung disease (PH-ILD;\u00a0WHO Group\u00a03) to improve exercise ability. The study establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and\u00a0WHO Group\u00a03 connective tissue disease (22%).  <\/li>\n<p> <\/ul>\n<p> <\/p>\n<p>  <strong><br \/>   SELECTED SAFETY INFORMATION: WARNINGS AND PRECAUTIONS<br \/>  <\/strong> <\/p>\n<p> <\/p>\n<ul type=\"disc\">  <\/p>\n<li style=\"margin-bottom:8pt;\">   Treprostinil is a pulmonary and systemic vasodilator. In patients with low systemic arterial pressure, treatment with Treprostinil may produce symptomatic hypotension.  <\/li>\n<p>  <\/p>\n<li style=\"margin-bottom:8pt;\">   Treprostinil inhibits platelet aggregation and increases the risk of bleeding.  <\/li>\n<p>  <\/p>\n<li style=\"margin-bottom:8pt;\">   Co-administration of a cytochrome P450 (CYP) 2C8 enzyme inhibitor (e.g., gemfibrozil) may increase exposure (both Cmax and AUC) to treprostinil. Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. Increased exposure is likely to increase adverse events associated with treprostinil administration, whereas decreased exposure is likely to reduce clinical effectiveness.  <\/li>\n<p>  <\/p>\n<li style=\"margin-bottom:8pt;\">   Like other inhaled prostaglandins, YUTREPIA may cause acute bronchospasm. Patients with asthma or chronic obstructive pulmonary disease (COPD), or other bronchial hyperreactivity, are at increased risk for bronchospasm. Ensure that such patients are treated optimally for reactive airway disease prior to and during treatment.  <\/li>\n<p>  <\/p>\n<li style=\"margin-bottom:8pt;\">   Most common adverse reactions with YUTREPIA (\u226510%) are cough, headache, throat irritation and dizziness.\n<p>  <\/li>\n<p> <\/ul>\n<p> <\/p>\n<p>  Prescribing Information and Instructions for Use for YUTREPIA (treprostinil) inhalation powder are available at<\/p>\n<p>   YUTREPIA.com.<\/p>\n<p> <\/p>\n<p>  <strong><br \/>   About\u00a0Liquidia Corporation<br \/>  <\/strong><\/p>\n<p>  Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company\u2019s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT<br \/>  <sup><br \/>   \u00ae<br \/>  <\/sup><br \/>  Technology. PRINT enabled the creation of YUTREPIA\u2122 (treprostinil) inhalation powder, a drug that has been approved for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PHILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit<\/p>\n<p>   <u><br \/>    www.liquidia.com<br \/>   <\/u><br \/>   .<\/p>\n<p> <\/p>\n<p>  <strong><br \/>   Cautionary Statements Regarding Forward-Looking Statements<br \/>  <\/strong><\/p>\n<p>  This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding our future results of operations and financial position, our strategic and financial initiatives, our business strategy and plans and our objectives for future operations, are forward-looking statements. Such forward-looking statements, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs), regulatory applications and related submission contents and timelines; our ability to successfully commercialize our products, including YUTREPIA, for which we obtain FDA or other regulatory authority approval; the acceptance by the market of our products, including YUTREPIA, and their potential pricing and\/or reimbursement by third-party payors, if approved (in the case of our product candidates) and whether such acceptance is sufficient to support continued commercialization or development of our products; the successful development or commercialization of our products, including YUTREPIA; our revenue from product sales and whether or not we may become profitable in the near term, or at all; future competitive or other market factors that may adversely affect the commercial potential for YUTREPIA; and our ability to execute on our strategic or financial initiatives, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein.\u00a0Despite the approval of YUTREPIA by the FDA, it is possible that commercialization of YUTREPIA may be blocked or delayed in connection with legal proceedings that have been initiated or that may in the future be initiated, or we may be required to pay damages, including royalties, in connection with our commercial launch, as a result of these legal proceedings. The denial of the motion for temporary restraining order and preliminary injunction in United Therapeutics\u2019 lawsuit against Liquidia in the U.S. District Court for the Middle District of North Carolina does not conclude the lawsuit and is not determinative of the final outcome of the lawsuit. The words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwould,\u201d and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in our filings with the\u00a0SEC, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. <\/p>\n<p> <\/p>\n<p>  <strong><br \/>   Company Contacts<br \/>  <\/strong> <\/p>\n<p> <\/p>\n<p>  <strong><br \/>   Investors:<br \/>  <\/strong><\/p>\n<p>  Jason Adair<\/p>\n<p>  Chief Business Officer<\/p>\n<p>  919.328.4350<\/p>\n<p>   jason.adair@liquidia.com<\/p>\n<div class=\"ads__inline\">\n<div id=\"js-dfp-tag-8lE\"  class=\"btf-bodymidpagetwothirdswidth-6\">          <script type=\"text\/javascript\">         googletag.cmd.push(function() {             \/\/ Check if ID matches ID in the window.adsList array before calling googletag.display             function isAdInAdsList(id) {             for (var i = 0; i < window.adsList.length; i++) {                 if (window.adsList[i].id === id) {                     return true;                 }             }             return false;         }         if (isAdInAdsList('js-dfp-tag-8lE')) {             googletag.display('js-dfp-tag-8lE');         }         });     <\/script> <\/div>\n<\/p><\/div>\n<p> <\/p>\n<p>  <strong><br \/>   Media Inquiries:<br \/>  <\/strong><\/p>\n<p>  Patrick Wallace<\/p>\n<p>  Director, Corporate Communications<\/p>\n<p>  919.328.4383<\/p>\n<p>   patrick.wallace@liquidia.com<\/p>\n<p>This article was originally published on Quiver News, read the full story.<\/p>\n<p class=\"body__disclaimer\">The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/section>\n<p>        <script type=\"text\/javascript\">   \/\/ add oddAd class to every odd instance of body .ads__inline for different placeholder styles   let articleAds = document.querySelectorAll('.ads__inline');   for (let i = 0, len = articleAds.length; i < len; i++) {     \/\/ Do the below only if the curent count is less than 12     if ((i < 12) &#038;&#038; (i % 2 === 0)) {       articleAds[i].className += ' oddAd';     }   } <\/script>                                               <\/p>\n<div class=\"jupiter22-c-tags jupiter22-c-tags-default\">\n<h3 class=\"jupiter22-c-tags-title\">         Tags       <\/h3>\n<div class=\"jupiter22-c-tags-container\">Stocks<\/div>\n<\/p><\/div>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Liquidia announces FDA approval and commercial launch of YUTREPIA for treating pulmonary arterial hypertension and PH-ILD. Quiver AI Summary Liquidia Corporation has announced that its inhalation powder YUTREPIA\u2122 (treprostinil) is now available for prescription at specialty pharmacies, following FDA approval on May 23, 2025, for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":11445,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"ocean_post_layout":"","ocean_both_sidebars_style":"","ocean_both_sidebars_content_width":0,"ocean_both_sidebars_sidebars_width":0,"ocean_sidebar":"","ocean_second_sidebar":"","ocean_disable_margins":"enable","ocean_add_body_class":"","ocean_shortcode_before_top_bar":"","ocean_shortcode_after_top_bar":"","ocean_shortcode_before_header":"","ocean_shortcode_after_header":"","ocean_has_shortcode":"","ocean_shortcode_after_title":"","ocean_shortcode_before_footer_widgets":"","ocean_shortcode_after_footer_widgets":"","ocean_shortcode_before_footer_bottom":"","ocean_shortcode_after_footer_bottom":"","ocean_display_top_bar":"default","ocean_display_header":"default","ocean_header_style":"","ocean_center_header_left_menu":"","ocean_custom_header_template":"","ocean_custom_logo":0,"ocean_custom_retina_logo":0,"ocean_custom_logo_max_width":0,"ocean_custom_logo_tablet_max_width":0,"ocean_custom_logo_mobile_max_width":0,"ocean_custom_logo_max_height":0,"ocean_custom_logo_tablet_max_height":0,"ocean_custom_logo_mobile_max_height":0,"ocean_header_custom_menu":"","ocean_menu_typo_font_family":"","ocean_menu_typo_font_subset":"","ocean_menu_typo_font_size":0,"ocean_menu_typo_font_size_tablet":0,"ocean_menu_typo_font_size_mobile":0,"ocean_menu_typo_font_size_unit":"px","ocean_menu_typo_font_weight":"","ocean_menu_typo_font_weight_tablet":"","ocean_menu_typo_font_weight_mobile":"","ocean_menu_typo_transform":"","ocean_menu_typo_transform_tablet":"","ocean_menu_typo_transform_mobile":"","ocean_menu_typo_line_height":0,"ocean_menu_typo_line_height_tablet":0,"ocean_menu_typo_line_height_mobile":0,"ocean_menu_typo_line_height_unit":"","ocean_menu_typo_spacing":0,"ocean_menu_typo_spacing_tablet":0,"ocean_menu_typo_spacing_mobile":0,"ocean_menu_typo_spacing_unit":"","ocean_menu_link_color":"","ocean_menu_link_color_hover":"","ocean_menu_link_color_active":"","ocean_menu_link_background":"","ocean_menu_link_hover_background":"","ocean_menu_link_active_background":"","ocean_menu_social_links_bg":"","ocean_menu_social_hover_links_bg":"","ocean_menu_social_links_color":"","ocean_menu_social_hover_links_color":"","ocean_disable_title":"default","ocean_disable_heading":"default","ocean_post_title":"","ocean_post_subheading":"","ocean_post_title_style":"","ocean_post_title_background_color":"","ocean_post_title_background":0,"ocean_post_title_bg_image_position":"","ocean_post_title_bg_image_attachment":"","ocean_post_title_bg_image_repeat":"","ocean_post_title_bg_image_size":"","ocean_post_title_height":0,"ocean_post_title_bg_overlay":0.5,"ocean_post_title_bg_overlay_color":"","ocean_disable_breadcrumbs":"default","ocean_breadcrumbs_color":"","ocean_breadcrumbs_separator_color":"","ocean_breadcrumbs_links_color":"","ocean_breadcrumbs_links_hover_color":"","ocean_display_footer_widgets":"default","ocean_display_footer_bottom":"default","ocean_custom_footer_template":"","ocean_post_oembed":"","ocean_post_self_hosted_media":"","ocean_post_video_embed":"","ocean_link_format":"","ocean_link_format_target":"self","ocean_quote_format":"","ocean_quote_format_link":"post","ocean_gallery_link_images":"on","ocean_gallery_id":[],"footnotes":""},"categories":[18],"tags":[],"class_list":["post-11444","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock","entry","has-media"],"_links":{"self":[{"href":"https:\/\/sharewatch.com\/wp\/wp-json\/wp\/v2\/posts\/11444","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sharewatch.com\/wp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sharewatch.com\/wp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sharewatch.com\/wp\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/sharewatch.com\/wp\/wp-json\/wp\/v2\/comments?post=11444"}],"version-history":[{"count":0,"href":"https:\/\/sharewatch.com\/wp\/wp-json\/wp\/v2\/posts\/11444\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sharewatch.com\/wp\/wp-json\/wp\/v2\/media\/11445"}],"wp:attachment":[{"href":"https:\/\/sharewatch.com\/wp\/wp-json\/wp\/v2\/media?parent=11444"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sharewatch.com\/wp\/wp-json\/wp\/v2\/categories?post=11444"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sharewatch.com\/wp\/wp-json\/wp\/v2\/tags?post=11444"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}